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Abstract
Background: Peripheral administration of lipopolysaccharide (LPS) induces inflammation and increases cerebral
prostaglandin E2 (PGE2) concentration. PGE2 is eliminated from brain across the blood-brain barrier (BBB) in mice,
and this process is inhibited by intracerebral or intravenous pre-administration of anti-inflammatory drugs and
antibiotics such as cefmetazole and cefazolin that inhibit multidrug resistance-associated protein 4 (Mrp4/Abcc4)-
mediated PGE2 transport. The purpose of this study was to examine the effect of LPS-induced inflammation on
PGE2 elimination from brain, and whether antibiotics further inhibit PGE2 elimination in LPS-treated mice.
Methods: [
3H]PGE2 elimination across the BBB of intraperitoneally LPS-treated mice was assessed by the brain
efflux index (BEI) method. Transporter protein amounts in brain capillaries were quantified by liquid
chromatography-tandem mass spectrometry.
Results: The apparent elimination rate of [
3H]PGE2 from brain was lower by 87%, in LPS-treated mice compared
with saline-treated mice. The Mrp4 protein amount was unchanged in brain capillaries of LPS-treated mice
compared with saline-treated mice, while the protein amounts of organic anion transporter 3 (Oat3/Slc22a8) and
organic anion transporting polypeptide 1a4 (Oatp1a4/Slco1a4) were decreased by 26% and 39%, respectively.
Either intracerebral or intravenous pre-administration of cefmetazole further inhibited PGE2 elimination in LPS-
treated mice. However, intracerebral or intravenous pre-administration of cefazolin had little effect on PGE2
elimination in LPS-treated mice, or in LPS-untreated mice given Oat3 and Oatp1a4 inhibitors. These results indicate
that peripheral administration of cefmetazole inhibits PGE2 elimination across the BBB in LPS-treated mice.
Conclusion: PGE2 elimination across the BBB is attenuated in an LPS-induced mouse model of inflammation.
Peripheral administration of cefmetazole further inhibits PGE2 elimination in LPS-treated mice.
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The blood-brain barrier (BBB), which is formed by the
tight junctions of brain capillary endothelial cells,
expresses various transporters to regulate exchange of
compounds between the brain and the circulating blood.
Organic anion transporters such as multidrug resis-
tance-associated protein 4 (Mrp4/Abcc4), organic anion
transporter 3 (Oat3/Slc22a8) and organic anion trans-
porting polypeptide 1a4 (Oatp1a4/Slco1a4) are involved
in the elimination of endogenous anionic compounds
across the BBB [1]. Mrp4 is expressed at the luminal
membrane of the BBB [2], while Oat3 is expressed at
the abluminal membrane of the BBB [3]. Oatp1a4 is
localized in both the abluminal and luminal membranes
[4]. Involvement of Oat3 and Oatp1a4 in the trans-BBB
elimination of various endogenous anionic compounds,
such as homovanillic acid and 24S-hydroxycholesterol,
has been demonstrated [3,5]. Moreover, we reported
that prostaglandin E2 (PGE2), which is an inflammatory
mediator, is eliminated across the BBB in normal mice,
and this elimination process involves Mrp4 [6]. Because
PGE2-metabolizing activity was not detected either in
rat brain or cerebral microvessels [7], PGE2 elimination
across the BBB is considered to be critical for control-
ling PGE2 function in the brain.
Excess PGE2 promotes excitatory signal transduction in
the brain, leading to fever progression and behavioral
abnormalities [8,9]. The concentration of PGE2 in the
brain is increased by endotoxin challenge during infection
[10,11]. Lipopolysaccharide (LPS), a gram-negative bacter-
ial cell surface proteoglycan, is one such endotoxin [11].
Intraperitoneal administration of LPS at the dose of more
than 1 mg/kg induces systemic inflammatory response
syndrome, including systemic and cerebral increase of
inflammatory cytokines and the changes of body tempera-
ture and locomotive activity [12,13]. Moreover, LPS at
doses of more than 1 mg/kg increases the PGE2 concen-
tration in the brain to 28-141 nM, which is 100- to 700-
fold greater than normal [14,15]. Although systemic or
intracerebral administration of LPS induces PGE2-produ-
cing enzymes, such as cyclooxygenase (COX)-2 and
microsomal prostaglandin E synthase (PGES), in the brain
[16-18], attenuation of PGE2 elimination across the BBB
may also contribute to the dramatic increase of brain
PGE2 level induced by LPS.
In patients with gram-negative bacterial infection, anti-
inflammatory drugs and antibiotics are administered for
p a l l i a t i v ec a r ea n dt r e a t m e n t[ 1 9 , 2 0 ] .W eh a v er e p o r t e d
that the elimination of PGE2 across the BBB was inhib-
ited by either intracerebral or intravenous administration
of antibiotics, such as cefmetazole and cefazolin, and also
by intracerebral administration of non-steroidal anti-
inflammatory drug (NSAIDs), such as indomethacin and
ketoprofen. These drugs strongly inhibit human MRP4-
mediated PGE2 transport activity, and Mrp4 is involved
in elimination of PGE2 across the BBB [6]. Oat3 accepts
PGE2 as a substrate [21]. Oatp1a4 and prostaglandin
transporter (Pgt/Slco2a1) were reported to be involved in
prostaglandin E1 transport from the circulating blood to
the brain [22]. These results raise the possibility that
administration of antibiotics and/or NSAIDs could facili-
tate the increase of PGE2 levels in the brain by interac-
tion at organic anion transport system(s) of the BBB,
thereby increasing the probability of cerebral adverse
effects. Indeed, fever is related to increased PGE2 in the
brain [8], and is a known adverse effect of cefmetazole
[23]. Thus, it is important to examine the effect of these
drugs on PGE2 elimination across the BBB in inflamma-
tion, in order to establish appropriate drug treatment of
infectious diseases.
Therefore, the purpose of this study was to investigate
the effect of LPS-induced inflammation on PGE2 elimina-
tion from the brain across the BBB, and to examine
whether antibiotics further inhibit the PGE2 elimination in
LPS-treated mice, using the brain efflux index (BEI)
method.
Methods
Reagents
Prostaglandin E2, [5,6,8,11,12,14,15-
3H(N)]- ([
3H]PGE2;
185.6 Ci/mmol) was purchased from PerkinElmer Life
and Analytical Sciences (Boston, MA, USA). Inulin
carboxyl, [carboxyl-
14C]- ([
14C]inulin; 1.9 mCi/g) was
purchased from Moravek Biochemicals (Brea, CA, USA).
Cefazolin sodium salt, cefmetazole sodium salt, cefotax-
ime sodium salt, cefsulodin sodium salt hydrate, ceftriax-
one disodium salt, indomethacin, ketoprofen and LPS
(from E. coli serotype O111:B4) were obtained from
S i g m a - A l d r i c h( S t .L o u i s ,M O ,U S A ) .C e f o t i a mw a sp u r -
chased from The United States Pharmacopeial Conven-
tion (Kansas City, MO, USA). All other chemicals were
commercial reagent-grade products.
Animals
Adult male C57BL/6J mice (20-30 g) and ddY mice (25-40
g) were purchased from Japan SLC (Hamamatsu, Japan).
All experiments conformed to the provisions of the Ani-
mal Care Committee, University of Toyama, and were
approved by the Animal Care Committee, Graduate
School of Pharmaceutical Sciences, Tohoku University. In
order to obtain the mouse model of inflammation (LPS-
treated mice), 3.0 mg/kg LPS was intraperitoneally admi-
nistered to mice 24 hours prior to experiments.
Mouse brain efflux index (BEI) method
In vivo mouse brain elimination experiments were per-
formed using the intracerebral microinjection technique
[6]. In brief, a C57BL/6J mouse was anesthetized by
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body weight) and placed in a stereotaxic frame (SR-5M;
Narishige, Tokyo, Japan). The applied solution, consisting
of [
3H]PGE2 (96 nCi) and [
14C]inulin (4.8 nCi) dissolved
in 0.3 μL extracellular fluid (ECF) buffer (122 mM NaCl,
25 mM NaHCO3,3m MK C l ,1 . 4m MC a C l 2,1 . 2m M
MgSO4, 0.4 mM K2HPO4, 10 mM D-glucose and 10 mM
HEPES, pH 7.4) with 0.1% ethanol in the presence or
absence of unlabeled compounds, was administered into
the secondary somatosensory cortex (S2) region of the
brain. The needle was left in the injection configuration
for an additional 4 min to prevent reflux of the injected
solution along the injection track, before being slowly
retracted. [
14C]Inulin is an impermeable marker used to
normalize the actual injection volume, as the injection
volume is small (0.3 μL). In the pre-administration study,
inhibitor solution (10 μL) at the indicated concentration
in ECF buffer with or without 0.25% dimethyl sulfoxide
(DMSO) was injected into the S2 region 5 min prior to
administration of the applied solution. To examine the
effects of benzylpenicillin and digoxin, inhibitor solution
containing 100 μM benzylpenicillin or 20 μM digoxin
was injected into the S2 region. As a control, ECF buffer
with or without 0.25% DMSO was injected. For the intra-
venous administration study, 200 μL of Ringer-HEPES
buffer (141 mM NaCl, 4 mM KCl, 2.8 mM CaCl2 and 10
mM HEPES-NaOH, pH 7.4) containing cefmetazole or
cefazolin was injected into the jugular vein 15 min prior
to administration of the applied solution. To test the
effect of amiodarone administration, 20 mg/kg amiodar-
one was intravenously administered 5 min prior to intra-
venous administration of cefmetazole or cefazolin. At a
designated time, the mouse was decapitated and the left
and right cerebrum and cerebellum were excised. Each
tissue was dissolved in 2 N NaOH (2 mL) at 55°C for 3 h,
and then mixed with 14 mL Hionic-Fluor (PerkinElmer
Life & Analytical Sciences). The radioactivity was mea-
sured in a liquid scintillation counter equipped with an
appropriate crossover correction for
3Ha n d
14C( L S C -
5100, Aloka, Tokyo, Japan).
The BEI value was defined according to Eqn. 1 and
the percentage of [
3H]PGE2 remaining in the ipsilateral
cerebrum (100-BEI) was determined using Eqn. 2:
BEI(%)=
Testsubstrate undergoingefﬂuxattheBBB
Testsubstrate injectedintothebrain
× 100 (1)
100−BEI (%)=
(Amountof[3H]PGE2 inthebrain/amountof[14C]inulininthebrain)
(Concentration of[3H]PGE2 ininjectate/concentration of[14C]inulinininjectate)
×100 (2)
As can be seen from these equations, increase of the
100-BEI value of [
3H]PGE2 indicates a decrease of PGE2
elimination rate from the brain across the BBB.
The apparent elimination rate constant (ke) was deter-
mined by fitting a semi-logarithmic plot of 100-BEI, i.e.,
the percentage remaining in the ipsilateral cerebrum,
versus time, using a nonlinear least-squares regression
analysis program (MULTI) [24]. To evaluate the inhibi-
tory effect on [
3H]PGE2 efflux across the BBB, the BEI
value of [
3H]PGE2 at 40 min was determined in the pre-
sence or absence of various drugs.
Preparation of brain capillary fraction from saline-treated
and 3.0 mg/kg LPS-treated mice
Mouse brain capillary fraction was prepared as described
[25]. All procedures were carried out at 4°C except for
perfusion. Mice were transcardially perfused with phos-
phate-buffered saline to remove blood under anesthesia
induced with pentobarbital, and then the cerebrum was
isolated. 20 cerebrums were dissected into 1-mm pieces,
and homogenized with a Potter-Elvehjem homogenizer
using 10 up and down no-rotated strokes by hand in 4-
fold volume solution B (101 mM NaCl, 4.6 mM KCl,
2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4,1 5m M
HEPES, pH 7.4) of brain weight. After the dextran (Mw
60,000-90,000, Sigma-Aldrich) was added to the homoge-
nate as the final concentration of 16%, the mixture was
c e n t r i f u g e da t4 5 0 0×gf o r1 0m i n .T h ep e l l e tw a ss u s -
pended in solution A (solution B containing 25 mM
NaHCO3,1 0m Mg l u c o s e ,1m Mp y r u v a t ea n d5g / L
bovine serum albumin) and passed through a 85 μm nylon
mesh, and the filtrate was passed over a column contain-
ing 350-500 μm glass beads, and then washed with 50 mL
solution A. The brain capillaries adhering to the beads
were detached to solution A by gentle agitation, and, as
soon as the beads sank, the supernatant including the
capillaries was collected. The supernatant was centrifuged
at 230 × g for 5 min. The pellet was suspended with solu-
tion B, and centrifuged at 1700 × g for 5 min. Again, the
pellet was suspended with solution B, and centrifuged at
1700 × g for 5 min. The pellet was suspended with hypo-
tonic buffer (10 mM Tris-HCl, 10 mM NaCl, 1.5 mM
MgCl2, pH 7.4) and sonicated. The capillaries were stored
at -80°C after measurement of the protein concentration
by the Lowry method using the DC protein assay reagent
(Bio-Rad, Hercules, CA, USA).
Quantification of transporter protein in mouse brain
capillaries by LC-MS/MS
The absolute amount of transporter protein in mouse
brain capillary endothelial cells was determined by mass
spectrometric analysis [26]. The brain capillary fraction
(50 μg protein) was suspended in 500 mM Tris-HCl
(pH 8.5), 7 M guanidium hydrochloride and 10 mM
EDTA, and the proteins were S-carbomoylmethylated.
The alkylated proteins were precipitated with a mixture
of methanol and chloroform. The precipitates were dis-
solved in 6 M urea in 100 mM Tris-HCl (pH 8.5),
diluted 5-fold with 100 mM Tris-HCl (pH 8.5) and
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WI, USA) at an enzyme/substrate ratio of 1:100 at 37°C
for 16 h. The tryptic digests were mixed with isotope-
labeled peptides as internal standards (Table 1) and for-
mic acid, and then centrifuged at 4°C and 17,360 × g for
5 min. The supernatants were subjected to LC-MS/MS
analysis.
The LC-MS/MS analysis was performed by coupling an
Agilent 1100 HPLC system (Agilent Technologies, Santa
Clara, CA, USA) to a triple quadrupole mass spectrometer
(API5000; Applied Biosystems, Foster City, CA, USA)
equipped with Turbo V ion source (Applied Biosystems).
Samples equivalent to 33.3 μg protein were injected onto a
Waters XBridge BEH130 C18 (1.0 × 100 mm, 3.5 μm) col-
umn together with 500 fmol of isotope-labeled peptides.
Mobile phases A and B consisted of 0.1% formic acid in
water and 0.1% formic acid in acetonitrile, respectively.
The peptides were separated and eluted from the column
at room temperature using a linear gradient with a 120-
min run time at a flow rate of 50 μL/min. The sequence
was as follows: (A:B), 99:1 for 5 min after injection, 50:50
at 55 min, 0:100 at 56 min and up to 58 min, 99:1 at
60 min and up to 120 min.
The eluted peptides were simultaneously and selectively
detected by means of electro-spray ionization in a multi-
plexed multiple reaction monitoring (MRM) mode, which
can quantify many molecules simultaneously. The dwell
time was 10 msec per MRM transition. Each molecule was
monitored with four sets of MRM transitions (Q1/Q3-1,
Q1/Q3-2, Q1/Q3-3, Q1/Q3-4) derived from one set of
unlabeled and isotope-labeled peptides (Table 1). Chroma-
togram ion counts were determined by using the data
acquisition procedures in Analyst software version 1.4.2
(Applied Biosystems). Signal peaks with a peak area count
of over 5000 detected at the same retention time as an iso-
tope-labeled peptide were defined as positive. When posi-
tive peaks were observed in three or four sets of MRM
transitions, the molecules were considered to be expressed
in brain capillaries, and then the protein expression
amounts were determined as the average of three or four
quantitative values. The limit of quantification (fmol/μg
protein) of non-detected molecules in the isolated mouse
brain capillary was defined as described previously [25]
(Table 1). In brief, the limit of quantification was defined
as the protein expression level which would give a peak
area count of 5000 in the chromatogram when a brain
capillary sample is measured by LC-MS/MS.
Data analysis
The apparent elimination rate constant (ke)i sp r e s e n t e d
as the mean ± S.D.. Other data are given as mean ± S.E.
M.. Statistical significance of differences between means
was determined by means of the unpaired two-tailed Stu-
dent’s t-test for two groups and one-way analysis of var-
iance followed by Dunnett’s test for more than two
groups.
Results
Effect of intraperitoneal pre-administration of LPS on
PGE2 elimination from mouse brain
Figure 1A shows the time-profile of the percentage of [
3H]
PGE2 remaining in the ipsilateral cerebrum after microin-
jection into the S2 region of LPS-treated mouse brain. The
percentage of [
3H]PGE2 remaining decreased in a time-
dependent manner in both saline-treated mice and LPS-
treated mice. The remaining percentage at 40 min was
3.46-fold greater in LPS-treated mice than in saline-treated
mice (p < 0.01), indicating that the elimination rate was
Table 1 Peptide probe sequences, selected ions for quantification and limit of quantification in isolated brain
capillaries of each protein with LC-MS/MS
MRM transition
Accession No. Synonym (gene name) Probe sequence Peptide
mass
Q1 Q3-1 Q3-2 Q3-3 Q3-4 Limit of quantification(fmol/μg)
Q3TZN9 Mrp4 APVLFFDR 963.5 482.8 796.4 697.4 584.3 437.2 0.0460
(Abcc4) APVL*FFDR 970.5 486.3 803.4 704.4 584.3 437.2
O88909 Oat3 YGLSDLFR 969.5 485.8 807.4 750.4 637.3 550.3 0.163
(Slc22a8) YGLSDL*FR 976.5 489.3 814.4 757.4 644.3 557.3
Q9EP96 Oatp1a4 EVATHGVR 867.5 434.7 640.4 569.3 468.3 331.2 0.441
(Slco1a4) EVATHGV*R 873.5 437.7 646.4 575.5 474.3 337.2
Q9EPT5 Pgt IFVDYGR 869.0 435.2 756.4 609.3 510.2 395.2 0.312
(Slco2a1)I F V*DYGR 875.0 438.2 762.4 615.3 510.2 395.2
The selected peptides were synthesized and their purity was checked with HPLC-UV according to the previous report [26]. The MRM transitions were determined
from MS/MS spectra obtained by direct infusion of 1 μM peptide solution at a flow rate of 5 μL/min with a syringe pump (Harvard) into the mass spectrometer.
Doubly charged precursor ions were selected (Q1). Four transitions per peptide (Q3-1, -2, -3 and -4), corresponding to high-intensity fragment ions, were
selected. The declustering potentials and collision energies were optimized to maximize signal strength. For the stable isotope-labeled peptides, precursor ions
and transitions corresponding to those of the unlabeled peptides were selected, with the same declustering potentials and collision energies as for the unlabeled
peptides. Bold letters with asterisks indicate amino acid residues labeled with stable isotope (
13Ca n d
15N). The limit of quantification was defined as the protein
expression level which would give a peak area count of 5000 in the chromatogram when a brain capillary sample is measured by LC-MS/MS.
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elimination rate constant (ke)o f[
3H]PGE2 calculated from
the slope was 5.52 × 10
-3 ± 2.67 × 10
-3 min
-1 in LPS-trea-
ted mice (mean ± S.D.), which was significantly lower, by
87.0%, than that in saline-treated mice (4.25 × 10
-2 ±
0.48 × 10
-2 min
-1, mean ± S.D.) (p < 0.01). No radioactivity
associated with this elimination process was detected in
the contralateral cerebrum or cerebellum (data not
shown).
The percentage recovery from brain of [
14C]inulin, a
non-permeable marker, was 50.9 ± 11.3% (n = 5), 31.0 ±
7.5% (n = 3) and 38.8 ± 6.4% (n = 3) at 5 min, 20 min
and 40 min, respectively, after microinjection in LPS-
treated mice. There was no significant difference
between these values. Moreover, the corresponding
values in saline-treated mice were 45.5 ± 14.2% (n = 3),
32.8 ± 5.7% (n = 3) and 56.7 ± 10.4% (n = 6) at 5 min,
20 min and 40 min after microinjection, respectively.
There was no significant difference in percentage recov-
ery at each time between LPS-treated mice and saline-
treated mice.
In LPS-treated mice, intracerebral co-administration of
3m Mu n l a b e l e dP G E 2 significantly increased the per-
centage of [
3H]PGE2 remaining in the brain at 40 min
after microinjection (114 ± 5%) compared to that in the
absence of unlabeled PGE2 (p < 0.05, Figure 1B). This
value was nearly identical to the y-intercept of the time-
profile of the percentage of [
3H]PGE2 remaining in LPS-
treated mice (108 ± 10% (mean ± S.D.), Figure 1A).
Effect of intraperitoneal pre-administration of LPS on
protein expression of organic anion transporters in
mouse brain capillaries
The transporter protein expression levels of Mrp4, Oat3,
Oatp1a4 and Pgt in mouse brain capillaries were simul-
taneously quantified by LC-MS/MS (Table 2). In the
brain capillaries of LPS-treated mice, Mrp4 protein
expression was not significantly altered. However, the
Figure 1 Effect of LPS treatment on elimination of [
3H]PGE2 from mouse brain. (A) Time-course of [
3H]PGE2 in the ipsilateral cerebrum after
intracerebral microinjection in LPS-treated mice (open circles) and saline-treated mice (closed circles). A mixture of [
3H]PGE2 (96 nCi) and [
14C]
inulin (4.8 nCi; internal reference) dissolved in 0.3 μL ECF buffer containing 0.1% ethanol was injected into the S2 region of mouse brain. Each
point represents the mean ± SEM (n = 4 - 5). **p < 0.01, significantly different from the saline-treated mice. (B) Effect of unlabeled PGE2 on the
percentage of [
3H]PGE2 remaining in the ipsilateral cerebrum at 40 min after intracerebral microinjection in LPS-treated mice. A mixture of [
3H]
PGE2 and [
14C]inulin dissolved in 0.3 μL ECF buffer containing 3 mM PGE2 was injected. Each column represents the mean ± S.E.M. (n = 3 - 4).
*p < 0.05, significantly different from the tracer only.
Table 2 Expression level of organic anion transporters in
brain capillaries of LPS-treated mice and saline-treated
mice.
Protein expression level (fmol/μg
protein)
Transporter Saline 3 mg/kg LPS Ratio
(LPS/Saline)
Mrp4 1.80 ± 0.20 1.50 ± 0.13 0.833
Oat3 1.25 ± 0.08 0.929 ± 0.068* 0.743
Oatp1a4 2.46 ± 0.31 1.50 ± 0.14** 0.610
Pgt N.D. N.D. -
Brain capillary-enriched fraction was prepared from ddY mice intraperitoneally
injected with 3 mg/kg LPS or saline. The fraction was digested with trypsin and
the digest was injected into LC-MS/MS together with internal standard peptides.
Each value represents the mean ± S.E.M. (n = 4). *p < 0.05 and **p < 0.01,
significantly different from the saline-treated mice. N.D: not detected.
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brain capillaries were significantly decreased by 26%
(p < 0.05) and 39% (p < 0.01), respectively, in LPS-trea-
ted mice compared to saline-treated mice. It is reported
that Pgt is expressed in rat cerebral endothelial cells
[35]. However, we found the protein expression level of
Pgt in the brain capillaries was below the detection limit
in both LPS-treated and saline-treated mice, indicating
that protein expression level of Pgt in mouse brain
capillaries is lower than that of Mrp4, Oat3 and
Oatp1a4.
Effect of intracerebral pre-administration of NSAIDs or
cephalosporins on PGE2 elimination from brain of LPS-
treated mice
The effects of intracerebral pre-administration of
NSAIDs or cephalosporins on [
3H]PGE2 elimination
from the brain of LPS-treated mice were investigated. As
shown in Table 3, the percentage of [
3H]PGE2 remaining
in the ipsilateral cerebrum in LPS-treated mice was sig-
nificantly increased by 1.46- and 1.49-fold by intracereb-
ral pre-administration of cefmetazole (5 mM) and
cefotaxime (5 mM), respectively, compared with the LPS-
treated control (p < 0.05). In contrast, ceftriaxone, cefa-
zolin, indomethacin or ketoprofen had no significant
effect on the level of [
3H]PGE2 remaining in the ipsilat-
eral cerebrum of LPS-treated mice, although these drugs
were reported to show an inhibitory effect on [
3H]PGE2
elimination in mice not treated with LPS [6]. Intracereb-
ral pre-administration of cefsulodin and clarithromycin,
which did not inhibit PGE2 elimination from the brain of
mice not treated with LPS [6], had no significant effect
on the level of [
3H]PGE2 remaining in the brain of LPS-
treated mice.
Inhibitory effect of intravenous pre-administration of
cefmetazole or cefazolin on PGE2 elimination from brain
of LPS-treated mice
The effects of intravenous pre-administration of cefme-
tazole or cefazolin on [
3H]PGE2 elimination from the
brain of LPS-treated mice were investigated. As shown
in Figure 2, the intravenous pre-administration of 200
mg/kg cefmetazole significantly increased the percentage
of [
3H]PGE2 remaining (102 ± 3%) in LPS-treated mice
(p < 0.05), compared with saline pre-administered LPS-
treated mice (78.1 ± 6.7%). In contrast, intravenous
administration of 200 mg/kg cefazolin had no significant
effect (78.4 ± 2.4%).
Involvement of Oat3 and/or Oatp1a4 in the inhibitory
effect of cefmetazole and cefazolin on PGE2 elimination
from mouse brain
To investigate the possible involvement of Oat3 and
Oatp1a4 in the inhibitory effect of intracerebral pre-
administration of cefmetazole and cefazolin on PGE2
elimination from the brain, Oat3 and Oatp1a4 were
selectively inhibited with benzylpenicillin (100 μM) and
digoxin (20 μM), respectively, in the brain of mice not
treated with LPS (Figure 3). In the case of intracerebral
pre-administration of ECF buffer with benzylpenicillin
and digoxin (control), the percentage of [
3H]PGE2
remaining was 32.8 ± 4.8%, which is similar to the value
Table 3 Effect of intracerebral pre-administration of antibiotics and NSAIDs (5 mM) on [
3H]PGE2 elimination from
brain across the BBB in LPS-treated mice
Compound Percentage of [
3H]PGE2 remaining
in ipsilateral cerebrum (100-BEI, %)
Percentage of control
Cephalosporins
Control 91.9 ± 6.6 100
Cefmetazole 133 ± 16* 146
Cefotaxime 136 ± 1* 149
Ceftriaxone 113 ± 11 124
Cefsulodin 94.2 ± 15.3 103
Cefazolin 85.7 ± 6.2 94.0
Other antibiotics and NSAIDs
Control
(0.25% DMSO)
97.2 ± 11.1 100
Indomethacin
(0.25% DMSO)
114 ± 9 117
Ketoprofen
(0.25% DMSO)
82.8 ± 5.8 85.2
Clarithromycin
(0.25% DMSO)
82.2 ± 16.4 84.6
Each compound or ECF buffer with or without 0.25% DMSO (control) was administered at 5 min prior to administration of [
3H]PGE2 in the brain of LPS-treated
mice. The percentage of [
3H]PGE2 in the ipsilateral cerebrum was determined at 40 min after intracerebral [
3H]PGE2 microinjection. Each value represents the
mean ± S.E.M. (n = 3-8). *p < 0.05, significantly different from control.
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(34.7%) [6]. When cefmetazole was pre-administered
with benzylpenicillin and digoxin in the brain, the per-
centage of [
3H]PGE2 remaining was increased by 1.95-
fold compared to the control (p < 0.01). Intracerebral
pre-administration of cefazolin with benzylpenicillin and
digoxin did not significantly affect the percentage of
[
3H]PGE2 remaining. These results suggest involvement
of Oat3 and/or Oatp1a4 in the inhibitory effect of cefa-
zolin in the brain.
Involvement of Oatp1a4 in the inhibitory effect of
cefmetazole and cefazolin in the circulation on PGE2
elimination from mouse brain
To investigate the involvement of Oatp1a4 in the effect of
intravenous administration of cefmetazole and cefazolin
on PGE2 elimination from the brain, Oatp1a4 was inhib-
ited by intravenous administration of amiodarone in mice
not treated with LPS. Intravenous administration of amio-
darone (20 mg/kg) did not affect the percentage of [
3H]
PGE2 remaining in the ipsilateral cerebrum (24.6 ± 5.5%)
compared with saline-only treatment (29.9 ± 4.3%). In the
case of 20 mg/kg amiodarone intravenous administration,
intravenous administration of 200 mg/kg cefmetazole or
200 mg/kg cefazolin did not cause a significant increase in
the percentage of [
3H]PGE2 remaining in the ipsilateral
cerebrum (29.3 ± 5.6% and 25.2 ± 6.6%, respectively;
Figure 4).
Discussion
The present study demonstrated that intraperitoneal LPS
administration resulted in attenuation of PGE2 elimina-
tion from the brain across the BBB (Figure 1A). The
elimination rate in LPS-treated mice was decreased to
13.0% of that in saline-treated mice. Intraperitoneal
administration of LPS at 3 mg/kg was reported to induce
severe inflammatory reaction (sepsis syndrome) in mice
[27,28]. Thus, it is suggested that PGE2 elimination
across the BBB might be attenuated in the case of severe
bacterial infection. These results indicate that the
increase of cerebral concentration of endogenous PGE2
in LPS-induced severe inflammation reflects not only
induction of PGE2-synthesizing enzymes, such as COX-2
and microsomal PGES, in the brain [18,29], but also
potent inhibition of PGE2 elimination from the brain.
In general, it is considered that the integrity of the BBB
is disrupted by LPS administration [13,30]. On the other
hand, the transport of BBB-impermeable compounds,
such as sodium fluorescein and serum albumin, was not
significantly changed by LPS administration [31,32]. There
was no significant variation in the percentage of [
14C]inu-
lin recovery between LPS-treated mice and saline-treated
mice in our study. Thus, it is suggested that the attenua-
tion of PGE2 elimination across the BBB by intraperitoneal
Figure 3 Inhibitory effect of intracerebral pre-administration of
cefmetazole or cefazolin on [
3H]PGE2 elimination from the
brain of LPS-untreated mice in the presence of benzylpenicillin
and digoxin. Either cefmetazole (5 mM) or cefazolin (5 mM) or ECF
buffer (ECF, control) was co-administered with 100 μM
benzylpenicillin and 20 μM digoxin to the S2 region 5 min prior to
administration of [
3H]PGE2 in the brain of mice without LPS
treatment. The 100-BEI value was determined 40 min after
intracerebral microinjection of [
3H]PGE2. Each column represents the
mean ± S.E.M. (n = 3). **p < 0.01, significantly different from control.
Figure 2 Effect of intravenous pre-administration of
cefmetazole or cefazolin on [
3H]PGE2 elimination from the
brain in LPS-treated mice. Cefmetazole (200 mg/kg), cefazolin (200
mg/kg) or Ringer-HEPES (control) was administered intravenously 15
min prior to administration of [
3H]PGE2 in LPS-treated mice. The
100-BEI value was determined 40 min after intracerebral
microinjection of [
3H]PGE2. Each column represents the mean ± S.E.
M. (n = 3). *p < 0.05, significantly different from control.
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Page 7 of 113.0 mg/kg LPS administration (Figure 1A) reflects the
reduction of PGE2 efflux transport capacity at the BBB,
but not disruption of the BBB.
We previously reported that Mrp4 was involved in PGE2
elimination from the brain across the BBB in normal mice
[6]. It has been reported that LPS administration alters the
protein expression and function of several transporters,
such as P-glycoprotein, at the BBB [30]. However, in LPS-
treated mice, the Mrp4 protein expression level was
unchanged in brain capillaries, compared with that in sal-
ine-treated mice (Table 2). Although the protein expres-
sion of Oat3 and Oatp1a4 in brain capillaries was
significantly decreased by 25.7% and 39.0%, respectively, in
LPS-treated mice (Table 2), these changes of Oat3 and
Oatp1a4 protein expression are insufficient to fully
account for the 87.0% decrease of the PGE2 elimination
rate. Furthermore, benzylpenicillin and digoxin treatment
did not affect PGE2 elimination from the brain (compare
Figure 3 and our previous results [6]). Under the condi-
tions we used, Oat3 and Oatp1a4 would be inhibited by
approximately 71% and 78%, respectively [33,34]. There-
fore, these results suggest that Oat3 and Oatp1a4 do not
play significant roles in the PGE2 elimination. Conse-
quently, the attenuation of PGE2 elimination cannot be
explained simply in terms of changes in protein expression
of relevant transporters at the BBB.
In the present study, we determined protein expression
levels in whole capillary endothelial cells, but not in
plasma membrane fraction. Therefore, a possible explana-
tion of our results is decreased protein levels of transpor-
ter(s) on the plasma membrane owing to induction of
internalization. It has been reported that LPS treatment
decreases the plasma membrane localization of Pgt at the
apical membrane of rat primary-cultured cerebral
endothelial cells [35]. On the other hand, the protein
expression level of Pgt was below the detection limit in
isolated brain capillaries of either saline- or LPS-treated
mice (Table 2). It is suggested that the protein expression
level of Pgt at the BBB is low compared with that of other
organic anion transporters, and so the alteration of plasma
membrane localization of Pgt is unlikely to have a major
influence on PGE2 transport across the BBB. Another pos-
sibility is a change in the molecular transport activity as a
result of protein modification. It has been reported that
LPS treatment decreased P-glycoprotein activity, without
changing its protein expression, via protein kinase C acti-
vation [36-38].
It is also conceivable that increased endogenous PGE2
inhibited the elimination of injected [
3H]PGE2 from the
brain. It was reported that endogenous PGE2 in the brain
after 1 mg/kg LPS administration is increased to approxi-
mately 28 nM from 0.2 nM [14], and intraperitoneal LPS
administration at 40 mg/kg increases the cerebral PGE2
concentration to approximately 141 nM [15]. Moreover,
i th a sb e e nr e p o r t e dt h a te x p r e s s i o no fC O X - 2a n d
microsomal PGES-1 in mouse brain capillaries is
increased by LPS administration [16,31]. In rats, PGE2-
derived immunoreactivity in brain capillaries of cerebral
cortex is markedly increased by intravenous administra-
tion of 2.5 mg/kg LPS, compared with saline control [39].
Therefore, there is a possibility that increased endogen-
ous PGE2 in brain capillary endothelial cells following
LPS administration may inhibit PGE2 transport via Mrp4
at the luminal membrane of brain capillary endothelial
cells.
[
3H]PGE2 elimination across the BBB in LPS-treated
mice was inhibited by co-administration of 3 mM unla-
beled PGE2 (Figure 1B). The percentage of [
3H]PGE2
remaining at 40 min was increased to 114% by 3 mM
unlabeled PGE2 co-administration (Figure 1B), and this
value was identical to the y-intercept of the time-profile
of the percentage of [
3H]PGE2 remaining in LPS-treated
mice (108%, Figure 1A). Thus, it is suggested that car-
rier-mediated PGE2 efflux transport is partially retained
in LPS-treated mice, and inhibition of PGE2 efflux trans-
port by drug administration could lead to the disappear-
ance of PGE2 elimination across the BBB. Intracerebral
Figure 4 Inhibitory effect of intravenous pre-administration of
cefmetazole or cefazolin on [
3H]PGE2 elimination from the
brain of LPS-untreated mice in the presence of amiodarone.
Either cefmetazole (200 mg/kg), cefazolin (200 mg/kg) or Ringer-
HEPES were administered with amiodarone (20 mg/kg) or saline
intravenously prior to intracerebral administration of [
3H]PGE2 in
mice not treated with LPS. The 100-BEI value was determined 40
min after intracerebral microinjection of [
3H]PGE2. Each point
represents the mean ± S.E.M. (n = 3 - 4).
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inhibited PGE2 elimination across the BBB in LPS-trea-
ted mice (Figure 2 and Table 3), suggesting that cefme-
tazole administration further inhibits PGE2 elimination
from the brain in this mouse model of inflammation.
Cefmetazole is known to induce fever [23], and fever is
associated with increased PGE2 in the brain [8]. There-
fore, the adverse effects of cefmetazole may be related
to its inhibitory effect on PGE2 elimination, which is
expected to result in increased cerebral accumulation of
PGE2. The plasma unbound concentration of cefmeta-
zole in mice can be calculated as 251 μM after intrave-
nous administration of 200 mg/kg cefmetazole from the
reported values of the volume of distribution of cefmeta-
zole, unbound fraction of drug in plasma and half-life in
circulating blood [40,41]. In humans, cefmetazole is
intravenously administered at the dosage of 2 g/human,
and the maximum serum unbound concentration of cef-
metazole was reported as 80.0 μM at this dose [40,42].
In addition, the IC50 value of cefmetazole for Mrp4-
mediated PGE2 transport was reported to be 10 μM[ 6 ] .
Because the unbound concentration of cefmetazole in
the circulating blood of both mouse and human is
higher than this IC50 value, it is possible that the inhibi-
tion of PGE2 elimination across the BBB following intra-
venous administration of cefmetazole can occur in
humans.
Cefmetazole in the circulation must enter brain capillary
endothelial cells in order to inhibit MRP4-mediated PGE2
transport at the luminal membrane of the BBB. We found
that the inhibitory effect of cefmetazole was blocked when
Oatp1a4 was inhibited by intravenous administration of
amiodarone (Figure 4), suggesting that Oatp1a4 mediates
the entry of cefmetazole from the circulating blood into
endothelial cells. This raises the possibility that co-admin-
istration of other Oatp1a4-substrate drugs might decrease
the cerebral adverse effects of cefmetazole via interaction
at Oatp1a4 on the luminal membrane of brain capillary
endothelial cells.
Either intracerebral or intravenous cefazolin inhibited
PGE2 elimination in mice not treated with LPS [6], and
intracerebral administration of benzylpenicillin and
digoxin suppressed the inhibitory effect of intracerebrally
administered cefazolin (Figure 3). Intravenous adminis-
tration of amiodarone also suppressed the inhibitory
effect of intravenous administered cefazolin (Figure 4).
These results suggest that cefazolin enters brain capillary
endothelial cells from the brain via Oat3 and/or Oatp1a4,
and from the circulation via Oatp1a4.
In LPS-treated mice, cefmetazole inhibited PGE2 elimina-
tion across the BBB, whereas cefazolin did not (Figure 2).
After intravenous administration of 200 mg/kg cefazolin,
the plasma unbound concentration of cefazolin in mice
reaches 445 μM, as calculated from the volume of
distribution of cefazolin, unbound fraction of drug in
plasma and half-life in circulating blood [40,41]. This value
is 5.5-fold higher than the Km value (80.9 μM) of Mrp4-
mediated cefazolin transport [43]. On the other hand, cefa-
zolin must be taken up into brain capillary endothelial cells
from circulating blood in order to inhibit Mrp4-mediated
PGE2 transport at the luminal membrane of the BBB. The
affinity of cefmetazole for Mrp4 is 8.1-fold higher than that
of cefazolin [6,43], suggesting that the local concentration
of cefazolin in brain capillary endothelial cells may not be
sufficiently high, compared with that of cefmetazole, to
inhibit Mrp4. This seems reasonable, because expression of
Oatp1a4 protein, which mediates cefazolin uptake into
brain capillary endothelial cells from the circulating blood,
is decreased in LPS-treated mice, so the local concentration
of cefazolin in brain capillary endothelial cells may not be
sufficiently high to inhibit Mrp4 at the luminal membrane
of the BBB.
The inhibitory effect of drugs on PGE2 elimination from
the brain was different in LPS-treated mice from that in
untreated mice. Intracerebral 5 mM pre-administration
of ceftriaxone, cefazolin, indomethacin and ketoprofen,
which inhibit PGE2 elimination across the BBB in mice not
treated with LPS [6], did not significantly inhibit PGE2
elimination in LPS-treated mice (Table 3). Furthermore,
intravenous administration of cefazolin had little effect in
LPS-treated mice (Figure 2), although intravenous adminis-
tration of cefazolin showed a significant inhibitory effect on
PGE2 elimination in mice not treated with LPS [6]. In con-
trast, intracerebral and intravenous administration of cef-
metazole inhibited PGE2 elimination in either LPS-treated
or -untreated mice. These results suggest that the PGE2
elimination process consists of a cefmetazole-sensitive pro-
cess and a cefazolin-sensitive process, and LPS treatment
mainly suppresses the cefazolin-sensitive process. Further
study will be needed to clarify in detail the mechanism of
PGE2 elimination from the brain and its regulation by LPS
treatment, in order to understand the regulatory mechan-
isms of cerebral PGE2 levels and the mechanisms of the
cerebral adverse effects of antibiotics.
Conclusion
Our results show that PGE2 elimination from the brain
across the mouse BBB is attenuated in LPS-induced
inflammation, and intravenous administration of cefmeta-
zole further increases the inhibition of PGE2 elimination.
These findings indicate that the possibility of cerebral
adverse effects should be carefully taken into account
when using antibiotics to treat severe bacterial infections.
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